Drug crystallization – implications for topical and transdermal delivery

Ghalioungui P. The Ebers papyrus; a new English translation, commentaries and glossaries. Cairo (Egypt): Academy of Scientific Research and Technology; 1987. p. 298.

Burton RJ, 1972, Witchcraft in the middle ages

10.1001/archderm.1962.01590110044005

10.1111/j.1365-2133.1965.tb14578.x

10.1038/jid.1955.131

10.1001/archderm.1963.01590190026002

Vickers CFH, 1966, Modern trends in dermatology, 84

10.1001/archderm.1964.01600050060012

10.1001/archderm.1965.01600120089022

10.1001/archderm.1966.01600290120022

10.1111/j.1365-2133.1969.tb15972.x

10.1039/c0cp02943b

10.1016/j.bbalip.2013.11.006

10.1038/jid.2013.517

10.1111/exd.12293

10.1001/archderm.1965.01600120093023

10.1016/S0190-9622(83)70072-1

10.1023/A:1015899721493

US FDA. Guidance for industry: topical dermatological drug product NDAs and ANDAs-in vivo bioavailability, bioequivalence, in vitro release, and associated studies. Silver Spring (MD): Draft Guidance, June 1998, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 1998.

US FDA, 2002, Fed Regist, 67, 35122

Japanese Division of Drugs. Guidance for bioequivalence studies of generic products for topical use. 2003 July; National Institute of Health Sciences, Japan.

10.5414/CPP46289

FDA Drug Safety Communication: Ongoing safety review of Evamist (estradiol transdermal spray) and unintended exposure of children and pets to topical estrogen. Silver Spring (MD), 2010 Jul 29.

FDA Drug Safety Newsletter, 2009, Postmarket Rev, 2, 574

Androgel 1% prescribing information. Physician’s Desk Reference 62nd edition. Montvale (NJ): Thomson PDR, 2007.

Sandrena 0.5 mg gel. Summary of product characteristics. Electronic Medicines Compendium [Internet]. [cited 2015 Dec]. Available from: http://www.medicines.org.uk.

10.1016/0378-5173(93)90118-Y

Calis KA, 1992, Clin Pharm, 11, 22

10.1016/j.tiv.2012.02.007

10.1517/17425240802500870

10.1016/j.ejpb.2014.08.007

10.1016/0378-5173(84)90043-7

10.1007/BF00456392

10.1111/j.1365-2230.1987.tb01937.x

10.1002/jps.20735

10.1002/9781118140505.ch15

Transdermal delivery of drugs based on crystal size. United States Patent Application Publication. US 2006/0078603 A1.

10.1615/CritRevTherDrugCarrierSyst.v16.i4.10

10.1016/j.vaccine.2004.06.041

10.1016/j.vaccine.2005.08.012

Higuchi T, 1960, J Soc Cosmet Chem, 11, 85

10.1002/jps.2600580912

10.1016/0378-5173(91)90337-N

10.1016/0378-5173(94)90395-6

10.1016/S0168-3659(96)01595-7

10.1016/S0378-5173(97)04897-7

10.1016/0168-3659(95)00062-D

10.1016/S0378-5173(03)00299-0

10.1016/S0378-5173(00)00610-4

10.1016/S0378-5173(01)00673-1

10.1016/S0378-5173(99)00345-2

10.1016/S0378-5173(00)00346-X

10.1016/S0378-5173(00)00603-7

10.1016/S1359-6446(04)03180-0

10.1016/j.ijpharm.2009.09.043

10.1002/jps.2600810803

Transcutol P. Technical Data Sheet. Gattefossé, France. 2011 Jul; p.1–3.

10.1016/j.ijpharm.2013.02.040

10.1016/j.ijpharm.2004.01.013

10.1366/000370207781540042

10.1159/000328729

10.1016/j.ijpharm.2013.08.086

10.1039/c4sm02786h

10.1111/j.2042-7158.1998.tb03357.x

Solubility parameter based drug delivery system and method for altering drug saturation concentration. US Patent 5,656, 286.

10.1016/j.ijpharm.2010.04.042

10.1007/s11095-012-0901-7

10.1016/j.ijpharm.2012.12.014

10.1016/j.ejpb.2005.02.001

10.1007/s00216-014-8311-9

10.1002/(SICI)1520-6343(1998)4:5+<S31::AID-BSPY4>3.0.CO;2-M

10.1002/1097-4555(200008/09)31:8/9<813::AID-JRS573>3.0.CO;2-7

10.1364/BIOMED.2012.JM3A.42

10.1016/j.ijpharm.2013.01.036

10.1007/s11095-013-1169-2

10.1016/j.ijpharm.2014.08.061

10.1126/science.1165758

10.1016/j.jconrel.2013.11.002

10.1016/S0939-6411(98)00055-1

10.1002/(SICI)1097-4636(19990315)44:4<397::AID-JBM5>3.0.CO;2-Q

10.1016/S0939-6411(03)00120-6

Barrett CW, 1969, J Soc Cosmet Chem, 20, 487